ECONOMIC EVALUATION OF ANIDULAFUNGIN FOR CANDIDEMIA OR INVASIVE CANDIDIASIS THERAPY IN KOREA

被引：0
|
作者：
Kim, H. J. [1 ]
Oh, J. J. [1 ]
Park, H. J. [1 ]
Ko, S. K. [1 ]
机构：
[1] Pfizer Pharmaceut Korea Ltd, Seoul, South Korea
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 04期
关键词：
D O I：
10.1016/j.jval.2012.03.1314
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A244 / A244
页数：1
相关论文
共 50 条
  • [41] TREATMENT AND PROPHYLAXIS OF INVASIVE CANDIDIASIS WITH ANIDULAFUNGIN, CASPOFUNGIN AND MICAFUNGIN - REVIEW OF THE LITERATURE
    Gloeckner, A.
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2011, 16 (04) : 167 - 179
  • [42] Anidulafungin exposure and population pharmacokinetics in critically ill patients with invasive candidiasis
    Elkayal, Omar
    Hoffert, Yannick
    Mertens, Beatrijs
    Van Daele, Ruth
    Lagrou, Katrien
    Wauters, Joost
    Spriet, Isabel
    Dreesen, Erwin
    INFECTION, 2024,
  • [43] COST-EFFECTIVENESS ANALYSIS OF ANIDULAFUNGIN IN THE TREATMENT OF INVASIVE CANDIDIASIS IN COLOMBIA
    Diaz, J. A.
    Urrego-Novoa, J. R.
    Moreno, J. A.
    Huerfanco, C.
    Prieto, V. A.
    VALUE IN HEALTH, 2015, 18 (07) : A870 - A870
  • [44] Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin - review of the literature
    A Glöckner
    European Journal of Medical Research, 16 (4)
  • [45] Candidemia and invasive candidiasis among hospitalized neonates and pediatric patients
    Harrington, Rachel
    Kindermann, Sylvia L.
    Hou, Qingjiang
    Taylor, Robert J.
    Azie, Nkechi
    Horn, David L.
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (10) : 1803 - 1812
  • [46] Invasive candidiasis and candidemia: from current opinions to future perspectives
    Rueping, Maria J. G. T.
    Vehreschild, Joerg-Janne
    Cornely, Oliver A.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (06) : 735 - 748
  • [47] Use of Pharmacokinetic-Pharmacodynamic Analyses To Optimize Therapy with the Systemic Antifungal Micafungin for Invasive Candidiasis or Candidemia
    Andes, David
    Ambrose, Paul G.
    Hammel, Jeffrey P.
    Van Wart, Scott A.
    Iyer, Varsha
    Reynolds, Daniel K.
    Buell, Donald N.
    Kovanda, Laura L.
    Bhavnani, Sujata M.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (05) : 2113 - 2121
  • [48] Geographic distribution of Candida spp. and incidence of multidrug resistant (MDR) isolates in recent clinical studies of anidulafungin for the treatment of candidemia/invasive candidiasis (C/IC)
    Hogan, P.
    Marcek, T.
    Vazquez, J. A.
    Paiva, J. A.
    Mootsikapun, P.
    Ostrosky-Zeichner, L.
    MYCOSES, 2011, 54 : 56 - 56
  • [49] Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis
    Neoh, Chin Fen
    Liew, Danny
    Slavin, Monica
    Marriott, Debbie
    Chen, Sharon C. -A.
    Morrissey, Orla
    Stewart, Kay
    Kong, David C. M.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (08) : 1906 - 1915
  • [50] COST-EFFECTIVENESS ANALYSIS OF ANIDULAFUNGIN FOR THE MANAGEMENT OF INVASIVE CANDIDIASIS IN COLOMBIAN ADULTS
    Gamboa N, Castano
    Reyes, J.
    Rodriguez, A.
    VALUE IN HEALTH, 2018, 21 : S229 - S229
12345